For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) closed at $25.0 up 2.59% from its previous closing price of $24.37. In other words, the price has increased by $2.59 from its previous closing price. On the day, 1.09 million shares were traded. NAMS stock price reached its highest trading level at $25.18 during the session, while it also had its lowest trading level at $24.135.
Ratios:
For a deeper understanding of NewAmsterdam Pharma Company NV’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.08 and its Current Ratio is at 21.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on July 17, 2025, initiated with a Neutral rating and assigned the stock a target price of $27.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $42.
On June 10, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $44.Stifel initiated its Buy rating on June 10, 2025, with a $44 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 16 ’25 when Kling Douglas F sold 51,043 shares for $21.10 per share. The transaction valued at 1,077,007 led to the insider holds 44,000 shares of the business.
Kling Douglas F sold 47,569 shares of NAMS for $1,019,648 on Jul 15 ’25. The Chief Operating Officer now owns 44,000 shares after completing the transaction at $21.44 per share. On Jul 14 ’25, another insider, NAP PoolCo B.V., who serves as the Affiliate of the company, bought 1,433,193 shares for $21.56 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 2815699968 and an Enterprise Value of 2076877440. For the stock, the TTM Price-to-Sale (P/S) ratio is 43.99 while its Price-to-Book (P/B) ratio in mrq is 3.61. Its current Enterprise Value per Revenue stands at 32.448 whereas that against EBITDA is -12.032.
Stock Price History:
The Beta on a monthly basis for NAMS is -0.02, which has changed by 0.4705882 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $27.29, while it has fallen to a 52-week low of $14.06. The 50-Day Moving Average of the stock is 19.31%, while the 200-Day Moving Average is calculated to be 19.22%.
Shares Statistics:
For the past three months, NAMS has traded an average of 848.00K shares per day and 891110 over the past ten days. A total of 112.51M shares are outstanding, with a floating share count of 62.40M. Insiders hold about 44.60% of the company’s shares, while institutions hold 57.07% stake in the company. Shares short for NAMS as of 1753920000 were 7179587 with a Short Ratio of 8.47, compared to 1751241600 on 6875637. Therefore, it implies a Short% of Shares Outstanding of 7179587 and a Short% of Float of 7.6.
Earnings Estimates
As of right now, 11.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.26 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$0.94 and -$1.45 for the fiscal current year, implying an average EPS of -$1.21. EPS for the following year is -$1.64, with 11.0 analysts recommending between -$0.8 and -$2.52.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for NAMS’s current fiscal year. The highest revenue estimate was $46.21M, while the lowest revenue estimate was $18.99M, resulting in an average revenue estimate of $27.17M. In the same quarter a year ago, actual revenue was $43.39M
